scholarly journals Concomitant Medication Use End Relative to Reference Period

2020 ◽  
Author(s):  
Keyword(s):  
Concomitant Medication ◽  
Medication Use ◽  
Reference Period

Alvimopan accelerates gastrointestinal recovery after bowel resection regardless of age, gender, race, or concomitant medication use

Surgery ◽  
2007 ◽  
Vol 142 (4) ◽  
pp. 478-486 ◽  
Author(s):  
Anthony J. Senagore ◽  
Joel J. Bauer ◽  
Wei Du ◽  
Lee Techner
Keyword(s):  
Concomitant Medication ◽  
Bowel Resection ◽  
Medication Use

scholarly journals Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors

Immunotherapy ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 141-149 ◽  
Author(s):  
Shipra Gandhi ◽  
Manu Pandey ◽  
Nischala Ammannagari ◽  
Chong Wang ◽  
Mark J Bucsek ◽  
...  
Keyword(s):  
Adverse Events ◽  
Clinical Benefit ◽  
Immune Checkpoint Inhibitors ◽  
Concomitant Medication ◽  
Checkpoint Inhibitors ◽  
Metastatic Cancer ◽  
Medication Use ◽  
Significant Difference ◽  
Β Blockers ◽  
The Impact

Aim: Patients receiving checkpoint inhibitors (CPI) are frequently on other medications for co-morbidities. We explored the impact of concomitant medication use on outcomes. Materials & methods: 210 metastatic cancer patients on CPI were identified and association between concomitant medication use and immune-related adverse events with clinical outcomes was determined. Results: Aspirin, metformin, β-blockers and statins were not shown to have any statistically significant difference on clinical benefit. 26.3% patients with clinical benefit developed rash versus 11.8% without clinical benefit (p < 0.05) on multivariate analysis. Conclusion: Use of common prescription and nonprescription medications in patients with multiple co-morbidities appears safe and does not have an adverse effect on CPI efficacy. The presence of rash predicted for a better response.

Clinical and biochemical parameters as predictors of response to checkpoint inhibitors (CPI): A single institution experience.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e14590-e14590 ◽  
Author(s):  
Shipra Gandhi ◽  
Manu Pandey ◽  
Nischala Ammannagari ◽  
Katy Wang ◽  
Karen L Vona ◽  
...  
Keyword(s):  
Clinical Benefit ◽  
Concomitant Medication ◽  
Checkpoint Inhibitors ◽  
Financial Burden ◽  
Objective Response ◽  
Medication Use ◽  
Absolute Lymphocyte Count ◽  
Disease Assessment ◽  
Laboratory Parameters ◽  
Predictors Of Response

e14590 Background: The benefit of CPI is limited to a subgroup of patients. Significant toxicity and financial burden make it imperative to identify biomarkers predictive of clinical benefit. We aimed to analyze if immune related adverse events (irAE), laboratory parameters (besides PD-L1 status), prior chemotherapy and concomitant medication use could predict response to CPI. Methods: 216 consecutive patients treated at RPCI with single/multiple CPI from 2011 to 2016 were identified. Demographics, irAE (CTCAE v4.03), concomitant medication use, response (RECIST v1.1) and laboratory parameters were recorded. Progression free (PFS) and overall survival (OS) were calculated. Clinical benefit (responder) was defined as objective response or stable disease with PFS ≥ 6 months. Statistical analysis was performed using SAS v9.4. Results: 185/216 patients (86%) had clinical outcomes with first CPI available (55.7% melanoma, 28.1% lung, 10.8% kidney, 3.8% bladder, 1.6% others), 14% died before disease assessment. Median age was 61 years; 64% were males. 31% were responders (R); 69% non-responders (NR). Median PFS and OS for R were not reached and for NR were 4.7/7 months (p < 0.001). 26% R developed rash vs. 12% NR (p = 0.02). irAE diarrhea was associated with better OS (p = 0.03); rash with better PFS (p = 0.007) and OS (p = 0.05). Concomitant beta-blocker/NSAID use was noted in 35%/28% R vs 20%/12% NR (p = 0.04; p = 0.01). Higher median absolute eosinophil (AEC) and absolute lymphocyte count (ALC) were noted in R (400 and 2000/µl in R vs. 300 and 1600/µl in NR; p = 0.008 and 0.024). NR were noted to have a higher median lactate dehydrogenase (LDH) of 565 vs. 503 (p < 0.001). AEC > 100/µl and ALC > 1000/ µl were associated with better OS (P = 0.03; P = 0.001). Absolute neutrophil count (ANC) > 7500/µl and leucocyte count > 8750/ µl were associated with inferior PFS (p = 0.005; P = 0.02) and OS (p = 0.002; p = 0.03). Pre-CPI chemotherapy did not correlate with response to CPI. Conclusions: Among irAE, diarrhea and rash predicted improved outcomes. Eosinophilia, lymphocytosis, neutrophilia, leukocytosis and LDH could serve as potential prognostic biomarkers to CPI. Prospective studies are warranted to validate these findings.

Project Data Sphere: A first look at prostate cancer including concomitant medication use, prognosis, and toxicity.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 5022-5022
Author(s):  
Anthony M. Joshua ◽  
Bethany Gill ◽  
Leila Khoja ◽  
Melania Pintilie ◽  
Kald Abdallah
Keyword(s):  
Prostate Cancer ◽  
Concomitant Medication ◽  
Medication Use ◽  
Project Data
Sign in / Sign up

Export Citation Format

Share Document